ReviewProceedings of the American Thoracic Society2006
Advances in the diagnosis and treatment of tuberculosis.
Review in Proceedings of the American Thoracic Society, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Interferon-Gamma Release Assay Testing for Latent Tuberculosis Infection: A Health Technology Assessment.Ontario health technology assessment series · 2024Pooled it
- Evaluation of interferon-gamma release assays for the diagnosis of tuberculosis: an updated meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2012Pooled it
- Systematic review of cost and cost-effectiveness of different TB-screening strategies.BMC health services research · 2011Pooled it
- Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.The Journal of antimicrobial chemotherapy · 2013Trial
- Identification and characterization of inhibitors of the tuberculosis phosphatase PstP.The Journal of biological chemistry · 2026Article
- Evaluation of a Fluorescence Immunoassay-Based IGRA for Latent Tuberculosis Diagnosis: A Simplified, Cost-Effective Alternative.Microorganisms · 2026Article
- Distinguishing tuberculosis from non-tuberculous mycobacteria and other respiratory conditions by microbiome patterns.Scientific reports · 2025Article
- Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls.Expert reviews in molecular medicine · 2024Review
- Construction of ceRNA regulatory networks for active pulmonary tuberculosis.Scientific reports · 2024Article
- An Overview of Various Rifampicin Analogs againstMedicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Loop-Mediated Isothermal Amplification-Integrated CRISPR Methods for Infectious Disease Diagnosis at Point of Care.ACS omega · 2023Review
- Performance of Bleach Method Sputum Smear Microscopy for the Diagnosis of Tuberculosis in a Highly Endemic District in Lima, Peru.International journal of environmental research and public health · 2022Article
- Evidence for Implementation: Management of TB in HIV and Pregnancy.Current HIV/AIDS reports · 2022Review
- The state of the art for artificial intelligence in lung digital pathology.The Journal of pathology · 2022Review
- First crystal structures of 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) from Mycobacterium tuberculosis indicate a distinct mechanism of intermediate stabilization.Scientific reports · 2022Article
- Article
- Development of a loop-mediated isothermal amplification (LAMP) method for specific detection of Mycobacterium bovis.PLoS neglected tropical diseases · 2021Article
- Characterization of antibody response against 16kD and 38kD ofAnnals of translational medicine · 2020Article
- Article
- GeneXpert of stool versus gastric lavage fluid for the diagnosis of pulmonary tuberculosis in severely ill adults.Infection · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Although truly major advances that would revolutionize tuberculosis (TB) diagnosis and treatment have not been realized, we are beginning to see the innovations that have been prompted by the recognition of the economic potential of the market for new diagnostic tests and treatments for TB and considerably increased public and private funding. Despite the enormous global burden of TB and the overall low rates of case detection worldwide, conventional approaches to diagnosis have, until recently, relied on tests that have major limitations. In this review of advances in diagnosis, we focus on strengths and limitations of newer tests that are available for the diagnosis of latent and active tuberculosis and rapid detection of drug resistance, specifically, tests that measure release of IFN-gamma in response to stimulation by Mycobacterium tuberculosis antigens, nucleic acid amplification for identification of M. tuberculosis complex, and rapid tests for detecting drug resistance. Standard regimens for treating TB have not changed for more than 30 yr and still require a minimum of 6 mo to have a high likelihood of a lasting cure. In this article, we focus on important changes in the philosophy of treatment, emphasizing the responsibility of the provider to assure successful completion of treatment, and on the roles of existing anti-TB agents and newer drugs such as rifabutin, rifapentine, and fluoroquinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.